The Group Curium is the world’s largest nuclear medicine company. At Curium, we have a singular focus – to develop, manufacture and supply world-class radiopharmaceutical products around the globe. With manufacturing facilities across Europe, Middle East and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 15 million patients annually. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. As a fast-growing company in a niche market, Curium is today owned by a private equity fund with LBO financing scheme.
With over 715 M € revenues in 2025, Curium International is specialized into the production and marketing of 25+ radiopharmaceuticals products, covering 12 indications (such as oncology, cardiology, neurology pulmonary…). Our network provides optimal coverage across the world in the interest of healthcare professionals and their patients, with nearly 2,100 experienced employees and a network of 3 large manufacturing sites (Petten, Saclay and Gebze), 47 PET dedicated sites and 27 radiopharmacies.
